Literature DB >> 9208887

Paraneoplastic syndromes affecting the nervous system.

J O Dalmau1, J B Posner.   

Abstract

Paraneoplastic syndromes can affect virtually any portion of the nervous system. Most paraneoplastic syndromes are believed to be caused by an autoimmune reaction to an "onconeural" antigen shared by the cancer and the nervous system. The immune reaction may retard growth of the cancer, but it also damages the nervous system. Specific autoantibodies found in some individual paraneoplastic syndromes are usually associated with specific tumors. Neurological disorders, clinically and pathologically identical to paraneoplastic syndromes, may occur in some patients without cancer, but paraneoplastic antibodies are not found in these patients. The diagnosis of a paraneoplastic syndrome is based on its increased incidence in patients with cancer, the occasional response of the neurological syndrome to treatment of the underlying cancer, or the presence of specific autoantibodies. Some paraneoplastic syndromes respond to treatment of the underlying cancer or to immunosuppression but, for most syndromes, no effective treatment exists.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208887

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  13 in total

1.  Isolated paraneoplastic optic neuropathy associated with small-cell lung cancer and anti-CV2 antibodies.

Authors:  Adrián Arés-Luque; L A García-Tuñón; A Saiz; B C Cabezas; L E Hernández-Echebarría; M Franco; A Toribio; J Tejada; F Graus
Journal:  J Neurol       Date:  2007-04-02       Impact factor: 4.849

2.  A possible paraneoplastic neuromyelitis optica associated with lung cancer.

Authors:  Giuseppe De Santis; Luisa Caniatti; Alessandro De Vito; Riccardo De Gennaro; Enrico Granieri; Maria Rosaria Tola
Journal:  Neurol Sci       Date:  2009-06-30       Impact factor: 3.307

Review 3.  Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.

Authors:  M Abu-Shakra; D Buskila; M Ehrenfeld; K Conrad; Y Shoenfeld
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

4.  Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study.

Authors:  Bruno Gagnon; Graeme Low; Gil Schreier
Journal:  J Psychiatry Neurosci       Date:  2005-03       Impact factor: 6.186

5.  Current approaches to the treatment of paraneoplastic encephalitis.

Authors:  Wolfgang Grisold; Bruno Giometto; Roberta Vitaliani; Stefan Oberndorfer
Journal:  Ther Adv Neurol Disord       Date:  2011-07       Impact factor: 6.570

6.  Paraneoplastic recurrent multifocal encephalitis presenting with epilepsia partialis continua.

Authors:  Melike Mut; David Schiff; Josep Dalmau
Journal:  J Neurooncol       Date:  2005-03       Impact factor: 4.130

7.  Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without anti-onconeural antibodies.

Authors:  J C Antoine; J F Mosnier; L Absi; P Convers; J Honnorat; D Michel
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-07       Impact factor: 10.154

8.  Immunomodulatory treatment trial for paraneoplastic neurological disorders.

Authors:  Steven Vernino; Brian Patrick O'Neill; Randolph S Marks; Judith R O'Fallon; David W Kimmel
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

Review 9.  Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy.

Authors:  Meleeneh Kazarian; Ite A Laird-Offringa
Journal:  Mol Cancer       Date:  2011-03-30       Impact factor: 27.401

Review 10.  Management of paraneoplastic syndromes in lung cancer.

Authors:  Leno Thomas; Young Kwok; Martin J Edelman
Journal:  Curr Treat Options Oncol       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.